Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 22

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 22
---
 Stock issuable upon the exercise of outstanding warrants as of December 31, 2024, having a weighted average exercise 
 price of $2.51 per share; and                                                                                                         |
| ● | 420,000                                                                                                                               
 shares of Common Stock reserved for future issuance pursuant to our existing stock incentive plan.                                    |

The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.

| 10 |

| CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC.PURSUANT TO 17 C.F.R. SECTION 200.83 |

<div align='center'>DILUTION</div>

If you purchase securities in this offering, assuming no sale of any pre-funded warrants and no exercise of the common warrants issued in connection with this offering, your ownership interest will be immediately diluted to the extent of the difference between the combined public offering price per share of our Common Stock and accompanying warrant in this offering and the as adjusted net tangible book value per share of our Common Stock immediately after giving effect to this offering.

Our net tangible book value as of December 31, 2024 was approximately $4.2 million, or approximately $0.29 per share of our Common Stock. Our net tangible book value is the amount of our total tangible assets minus total liabilities. Net tangible book value per share as of December 31, 2024 is our net tangible book value divided by the number of shares of Common Stock outstanding as of December 31, 2024.

After giving effect to the sale of the maximum number of securities offered hereby, or [●] shares of Common Stock (assuming no sale of any pre-funded warrants and no exercise of the common warrants) in this offering at a combined public offering price of $[●] per share of Common Stock and accompanying common warrant (the last reported sale price of our Common Stock on Nasdaq on [●], 2025), and after deducting estimated Placement Agent fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2024 would have been approximately $[●] million, or approximately $[●] per share of Common Stock. This amount represents an immediate increase in as adjusted net tangible book value of $[●] per share of Common Stock to our existing stockholders and an immediate dilution of $[●] per share of Common Stock to investors participating in this offering. We determine dilution per share of